产品
编 号：F747474
分子量：17307.71
分子量：17307.71
产品类型
规格
价格
是否有货
结构图
CAS No: 1834612-06-4
产品详情
生物活性：
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
体内研究：
Lumasiran sodium is a subcutaneously administered, liver-directed RNA interference (RNAi) therapeutic agent.
体外研究：
Lumasiran sodium can be used for the research of PH1. By silencing the gene encoding glycolate oxidase, Lumasiran sodium depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of PH1.
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
体内研究：
Lumasiran sodium is a subcutaneously administered, liver-directed RNA interference (RNAi) therapeutic agent.
体外研究：
Lumasiran sodium can be used for the research of PH1. By silencing the gene encoding glycolate oxidase, Lumasiran sodium depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of PH1.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备